HERAMED LIMITED (HMD)

Latest AI Signal: BUY
Status: EXPIRED
Days Old: 29

Confidence: 55%

Date: 22-04-2026

Price: $0.050

Last Price: $0.039

Post-Signal Peak Price: $0.050

Latest  HERAMED LIMITED(HMD)   News

19 Jul 2021, 09:00 PM

Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors

Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors HAIFA, Israel, July

BUY Confidence Medium

AI Confidence - 55 % model confidence

Business Overview

HERAMED LIMITED operates in the healthcare sector, focusing on the development and distribution of medical products and services. The company holds a niche market position with potential growth driven by increasing healthcare demands in emerging markets.

Financial Analysis

Cash Flow	Unknown
Debt	Unknown
Profitability	Unknown
Revenue Trend	Unknown

Technical Analysis

Trend	Bullish
Momentum	Moderate
RSI Signal	Neutral
Support Level	$ 0.0450
Resistance Level	$ 0.0600

Valuation

Valuation - Undervalued

Current price appears attractive relative to sector peers and historical price levels, suggesting upside potential.

Catalysts

• Potential new product launches or regulatory approvals.

• Expansion into new regional markets could drive revenue growth.

Recommendation

Action - Buy

Timeframe - Medium Term

HERAMED LIMITED shows promising technical signals and undervaluation relative to peers. While financial data is limited, growth catalysts and market positioning support a medium-term buy recommendation.